Загрузка...
Sofosbuvir: A novel treatment option for chronic hepatitis C infection
Hepatitis C currently infects more than 170 million people around the world, leading to significant morbidity and mortality. The current standard of care for HCV infection, including one of the two protease inhibitors, telaprevir or boceprevir, for 12-32 weeks, along with pegylated interferon alfa-2...
Сохранить в:
| Опубликовано в: : | J Pharmacol Pharmacother |
|---|---|
| Главные авторы: | , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Medknow Publications & Media Pvt Ltd
2014
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4231565/ https://ncbi.nlm.nih.gov/pubmed/25422576 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/0976-500X.142464 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|